Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anxiety Disorders Age: Adult |
Dose: Oral – 1-6 mg/day Frequency: in 2 or 3 divided doses Note: Maximum 10 mg/day. Elderly: Half the usual adult dose or less. Hepatic impairment (Mild to moderate): May require reduced doses. Hepatic impairment (Severe): Contraindicated. |
|
Indication: Insomnia associated with anxiety Age: Adult |
Dose: Oral – 1-4 mg/day Frequency: at bedtime Note: Elderly: Half the usual adult dose or less. Hepatic impairment (Mild to moderate): May require reduced doses. Hepatic impairment (Severe): Contraindicated. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Status Epilepticus Age: Infants and children |
Dose: Intravenous – 0.05-0.1 mg/kg Duration: over 2-5 minutes Note: not to exceed 4 mg/dose; may repeat every 10-15 minutes as needed |
|
Indication: Status Epilepticus Age: Infants and children |
Dose: Intravenous – 0.1 mg/kg Note: slow intravenous rate not to exceed rate of 2 mg/minute; not to exceed dose of 4 mg |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: by mouth (oral) – Dose adjustment not necessary Note: Renal impairment |
|
Condition: Mild-to-moderate renal impairment |
Dose: intravenous/intramuscular – Use with caution Note: Renal impairment |
Administration
- Can take with/without food
- Regular timing
Side Effect
- Sedation
- drowsiness
- ataxia
- dizziness
- confusion
- depression
- unmasking of depression
- hypotension
- fatigue
- muscle weakness
- asthenia
- transient anterograde amnesia or memory impairment
- changes in vital signs (eg resp rate, BP)
- Thrombocytopenia
- agranulocytosis
- pancytopenia
- hyponatraemia
- disinhibition
- euphoria
- suicidal ideation
- nausea
- constipation
- change in libido
- impotence
- decreased orgasm
- Increase in bilirubin
- liver transaminases or alkaline phosphatase
- Resp depression
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Barbiturates, Phenothiazines, Antidepressants (Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram, Venlafaxine, Duloxetine), MAOIs (Phenelzine, Tranylcypromine, Selegiline, Moclobemide)
|
Additive CNS effects
|
|
Scopolamine
|
May increase sedation, hallucinations and irrational behaviour
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe hepatic impairment
|
Risk of hepatic encephalopathy
|
|
Respiratory depression
|
Can worsen breathing difficulty
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store between 20-25°C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.